Press Release December 09, 2014

BioPharm Insight Ranks Goodwin Top Legal Advisor for Biotech and Pharma Licensing Agreements

BioPharm Insight recently ranked Goodwin among the most active legal advisers for global, North American and European biotech and pharma licensing agreements for the 12 months ending September 30, 2014. In the trailing twelve months, Goodwin advised on 26 licensing agreements collectively valued at more than USD$2.7 billion, resulting in the following rankings:

  • #1 in global volume (26 deals, USD$2.714 billion)
  • #1 in North American volume (26 deals, USD$2.714 billion)
  • #1 in European volume (14 deals, USD$2.311 billion)

Goodwin also ranked among the top five legal advisors in terms of deal value in each of the global, North American and European tables.

Goodwin’s Life Sciences Practice is regularly recognized for its excellence and has been named the Law Firm of the Year in Biotechnology Law by U.S. News-Best Lawyers three years in a row (2015, 2014, 2013). The practice represents more than 400 private and public life sciences companies, from start-ups to Fortune 100 corporations, as well as 200 private equity, venture capital and investment banking companies. The practice includes more than 100 attorneys and is co-chaired by partners Mitchell Bloom and Kingsley Taft.